NO20082379L - Process for Preparation of Purified Crystalline CCI-779 - Google Patents

Process for Preparation of Purified Crystalline CCI-779

Info

Publication number
NO20082379L
NO20082379L NO20082379A NO20082379A NO20082379L NO 20082379 L NO20082379 L NO 20082379L NO 20082379 A NO20082379 A NO 20082379A NO 20082379 A NO20082379 A NO 20082379A NO 20082379 L NO20082379 L NO 20082379L
Authority
NO
Norway
Prior art keywords
preparation
purified crystalline
crystalline cci
cci
purified
Prior art date
Application number
NO20082379A
Other languages
Norwegian (no)
Inventor
Wei Tong
Subodh S Deshmukh
Chunhao Zhang
Clifford William Coughlin
Adam P Michaud
Lynn M Phelan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20082379L publication Critical patent/NO20082379L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer renset krystallinsk CCI-779 og fremgangsmåter for fremstilling av denne.The present invention provides purified crystalline CCI-779 and processes for its preparation.

NO20082379A 2005-12-07 2008-05-26 Process for Preparation of Purified Crystalline CCI-779 NO20082379L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74800605P 2005-12-07 2005-12-07
PCT/US2006/046444 WO2007067565A1 (en) 2005-12-07 2006-12-06 Process for the preparation of purified crystalline cci-779

Publications (1)

Publication Number Publication Date
NO20082379L true NO20082379L (en) 2008-09-04

Family

ID=37891446

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082379A NO20082379L (en) 2005-12-07 2008-05-26 Process for Preparation of Purified Crystalline CCI-779

Country Status (18)

Country Link
US (1) US7553843B2 (en)
EP (1) EP1957500A1 (en)
JP (1) JP2009518413A (en)
KR (1) KR20080077618A (en)
CN (1) CN101321769A (en)
AR (1) AR058282A1 (en)
AU (1) AU2006322029A1 (en)
BR (1) BRPI0619493A2 (en)
CA (1) CA2630784A1 (en)
CR (1) CR9988A (en)
EC (1) ECSP088517A (en)
GT (1) GT200800089A (en)
IL (1) IL191546A0 (en)
NO (1) NO20082379L (en)
PE (1) PE20071041A1 (en)
RU (1) RU2008121240A (en)
TW (1) TW200732342A (en)
WO (1) WO2007067565A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051960A2 (en) 2009-09-25 2011-05-05 Cadila Healthcare Limited Process for the preparation of rapamycin derivatives
CN109020995A (en) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 A kind of crystal form object of tesirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358909A (en) * 1991-02-27 1994-10-25 Nippon Steel Corporation Method of manufacturing field-emitter
US5358908A (en) * 1992-02-14 1994-10-25 Micron Technology, Inc. Method of creating sharp points and other features on the surface of a semiconductor substrate
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
DK1319008T3 (en) 2000-09-19 2009-02-09 Wyeth Corp Water-soluble rapamycin esters
FR2826961B1 (en) * 2001-07-06 2005-09-30 Atofina PROCESS FOR THE PREPARATION OF (METH) ACRYLIC ANHYDRIDE
CA2528173A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
ES2287772T3 (en) 2003-08-07 2007-12-16 Wyeth REGIONAL ELEMENT SYNTHESIS OF CCI-779.
SG145716A1 (en) 2003-09-03 2008-09-29 Wyeth Corp Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same
DE602005010228D1 (en) 2004-04-14 2008-11-20 Wyeth Corp METHOD OF PREPARING RAPAMYCIN-42 ESTERS AND FK-506-32 ESTERS WITH DICARBOXYLIC ACID, PREPARATIONS FOR RAPAMYCIN CONJUGATES AND ANTIBODIES
AU2005238431A1 (en) 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
JP2008517874A (en) 2004-08-10 2008-05-29 ワイス CCI-779 derivatives and methods for their preparation
ATE549342T1 (en) 2004-12-20 2012-03-15 Wyeth Llc RAPAMYCIN ANALOGS AND THEIR USES IN THE TREATMENT OF PROLIFERATIVE, INFLAMMATORY AND NEUROLOGICAL DISORDERS
EP1828203A2 (en) 2004-12-20 2007-09-05 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
CA2595766A1 (en) * 2005-02-09 2006-08-17 Wyeth Cci-779 polymorph and use thereof
CN101133066A (en) 2005-03-02 2008-02-27 惠氏公司 Recovery of CCI-779 from mother liquors
CN101137659A (en) 2005-03-07 2008-03-05 惠氏公司 Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin

Also Published As

Publication number Publication date
CN101321769A (en) 2008-12-10
CR9988A (en) 2008-07-29
AU2006322029A1 (en) 2007-06-14
TW200732342A (en) 2007-09-01
ECSP088517A (en) 2008-07-30
KR20080077618A (en) 2008-08-25
US20070129395A1 (en) 2007-06-07
GT200800089A (en) 2008-12-04
AR058282A1 (en) 2008-01-30
JP2009518413A (en) 2009-05-07
RU2008121240A (en) 2010-01-20
EP1957500A1 (en) 2008-08-20
US7553843B2 (en) 2009-06-30
WO2007067565A1 (en) 2007-06-14
IL191546A0 (en) 2008-12-29
CA2630784A1 (en) 2007-06-14
PE20071041A1 (en) 2007-12-07
BRPI0619493A2 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
MX2007005221A (en) Ascomycin crystalline forms and preparation thereof.
NO20071050L (en) Rapamycin polymorph II and uses thereof
TW200801262A (en) Method for purifying silicon
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
ATE497492T1 (en) CLEANING MONTELUKAST
ATE528989T1 (en) CRYSTALLINE SOLID RASAGILIN BASE
DK1836169T3 (en) COMPOSITIONS AND PROCEDURES FOR TREATING CELL PROLIFERATION DISEASES
WO2007022459A3 (en) Processes and intermediates
DE602006020327D1 (en) 2-PHENOXY-N- (1,3,4-THIADIZOL-2-YL) PYRIDINE-3-AMINDER INHIBITOR FOR THE TREATMENT OF THROMBOEMBOLIC ILLNESSES
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
NO20076371L (en) Process for the preparation of phenolic 4-biphenylylazetidin-2-ones
NO20063196L (en) New fused pyrrolocarbazoles
ATE393764T1 (en) POLYMORPHOUS FORMS OF VALSARTAN
NO20071254L (en) Process for the preparation of irbesartan and its intermediates.
NO20072473L (en) Process for the preparation of quinoline compounds and derived products
ATE410166T1 (en) 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCINOLINE DERIVATIVES FOR THE TREATMENT OF INFERTILITY
NO20060535L (en) Aztreonam-L-lysine and methods for preparing it
WO2006132739A3 (en) Novel chemical compounds
NO20083751L (en) Methods for the treatment of cognitive and other diseases
NO20073725L (en) CCI-779 polymorph and its use
DK1926732T3 (en) PROCEDURE FOR THE PREPARATION OF CARBAPENNAM RELATIONS
NO20073276L (en) Method for the preparation of aminoethoxybenzyl alcohols
WO2010148177A3 (en) Compounds, compositions, methods of synthesis, and methods of treatment
NO20091140L (en) Process for the preparation of polyester nanocomposites
WO2006127458A3 (en) Novel chemical compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application